PURPOSE: The precise mechanism of action of bacillus Calmette-Guerin (BCG) in @entity150 treatment remains poorly understood. Whether @entity150 cells are destroyed by nonspecific mechanisms or targeted by specifically activated lymphocytes recognizing cognate antigens is unclear. To investigate a possible cross-reactivity between BCG and bladder cell @entity5 , we tested before BCG treatment the lymphoproliferation of peripheral blood lymphocytes against several mycobacterial antigens, including the secreted fibronectin binding antigen 85 complex from BCG ( @entity19338 ) in @entity1 with superficial @entity150 compared to control matched @entity1 . MATERIALS AND METHODS: Using a whole blood assay, T cell response against purified protein derivative, BCG extract, whole BCG, purified @entity19338 , and the nonspecific mitogens pokeweed and phytohemagglutinin was investigated in 79 @entity1 with superficial @entity150 before BCG and in 39 control subjects without @entity5 matched for age and sex. Neither group had a history of @entity378 . Lymphoproliferation was measured with a @entity665 uptake assay on day 7 of culture. RESULTS: Of the 79 @entity1 with superficial @entity1606 , a significant lymphoproliferative response before BCG against @entity4035 , BCG extract, whole BCG and @entity19338 was observed in 65 (82.2%), 67 (84.81%), 30 (37.97%) and 49 (62.02%) @entity1 , respectively. Of the 39 controls only 26 (64.1%), 23 (58.9%), 3 (7.7%) and 3 (7.7%) @entity1 , respectively, had a significant lymphoproliferation against @entity4035 , BCG extract, BCG and @entity19338 (p >0.05, p = 0.004, p = 0.00001 and p = 0.00001, respectively). In terms of lymphoproliferative levels, @entity1 with superficial @entity1606 also showed a significantly higher response against @entity4035 (p = 0.000012), BCG extract (p = 0.000001), @entity19338 (p = 0.000001), whole BCG (p = 0.00001) and pokeweed (p = 0.01) than controls but not against phytohemagglutinin. CONCLUSIONS: @entity1 with superficial @entity1606 demonstrate an increased lymphoproliferation against mycobacterial antigens before BCG compared to control subjects. Although a nonspecific activation of the immune system cannot be excluded at this stage, our data may suggest the possible existence of @entity150 antigens cross-reactive with mycobacterial antigens responsible for boosting precursor cells witnessing previous contacts with mycobacteria. The implication of these findings in the antitumoral mechanism of action of BCG are under investigation.

XXXX and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4035 :: ('MESH:C535387', 'Disease') :: ['PPD'] @entity19338 :: ('MESH:C093656', 'Chemical') :: ['AG 85'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy', 'tumors'] @entity665 :: ('CHEBI:53526', 'Chemical') :: ['tritiated thymidine'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder tumor', 'bladder tumors', 'bladder cancer'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['transitional cell carcinoma'] @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']
@entity150 :: (MESH:D001749,Disease) :: ['Superficial bladder tumors']
